Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
The aim of this study was to analyze the susceptibility trends to seven antibiotics of Bacteroides fragilis group isolates based on three survey studies performed by the Committee of Anaerobic Bacteria between 1989 and 2002. Fifty three, 82 and 65 B. fragilis group isolates were collected during each period. The antimicrobial agents included were: ampicillin, ampicillin-sulbactam (2:1), cefoxitin, piperacillin, imipenem, clindamycin, and metronidazole. Minimal inhibitory concentrations (MICs) were determined according to the reference agar dilution method described by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). The most active antibiotics for B. fragilis and non-B. fragilis species throughout the three periods were: imipenem with 99.1 and 100% of activity, respectively, and metronidazole with 100% of activity. The susceptibility to ampicillin-sulbactam showed a decrease, from 100% to 90.3% and to 82.4 % in the last period, for both B. fragilis and non-B. fragilis species, respectively. The overall susceptibility rates for cefoxitin, piperacillin, and clindamycin were significantly different between B. fragilis and non-B. fragilis species (84.2% vs. 56.5%; 85.9% vs. 66.7% and 88.8% vs. 64.7%, respectively, p < 0.05). Cefoxitin was the antibiotic that showed more variations as regards periods and species. The susceptibility rates for clindamycin were low, about 60%, for non-B. fragilis species during the last two periods. The variations observed in the susceptibility patterns of the B. fragilis group isolates emphasize the need to continue monitoring the emergence of resistance in order to guide the election of the most appropriate antibiotic therapy scheme for anaerobic infections.
Fernández Canigia
L
L
Subcomisión de Bacterias Anaerobias (SADEBAC), Asociación Argentina de Microbiología, Deán Funes 472/76 (C1214AAD) Ciudad Autónoma de Buenos Aires, Argentina. lfcanigia@labdyl.com.ar
Castello
L
L
Di Martino
A
A
Greco
G
G
Legaria
M C
MC
Litterio
M
M
Predari
S C
SC
Rollet
R
R
Rossetti
A
A
Carloni
G
G
Sarchi
M I
MI
Bianchini
H
H
D000667:Ampicillin / Q000494:pharmacology; D000668:Ampicillin Resistance; D001118:Argentina / Q000453:epidemiology; D001439:Bacteroides / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D001442:Bacteroides Infections / Q000453:epidemiology / Q000382:microbiology*; D001441:Bacteroides fragilis / Q000187:drug effects* / Q000302:isolation & purification; D002440:Cefoxitin / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D012189:Retrospective Studies; D013045:Species Specificity; D013407:Sulbactam / Q000494:pharmacology; D014505:Urban Population
D008795:Metronidazole; D002981:Clindamycin; D002440:Cefoxitin; D015378:Imipenem; D000667:Ampicillin; D013407:Sulbactam; D010878:Piperacillin